Company Overview and News

 
Mammoth Energy: Unsustainable Contract, Sum-Of-The-Parts Indicate 50% Downside

2018-04-24 seekingalpha
Sum of the parts and peer comps suggests 50%+ of value is due to its new T&D infrastructure business.
Upvote Downvote

 
Hi-Crush: Keep Your Eyes On The Prize

2018-04-22 seekingalpha
Plenty of bearish sentiment remains about rails and incoming supply, but oil trends up with OPEC support.
Upvote Downvote

 
Hi-Crush Partners LP Announces Increase in Distribution to $0.225 per Unit for the First Quarter of 2018, Provides Unit Buyback Program Update

2018-04-19 globenewswire
HOUSTON, April 19, 2018 (GLOBE NEWSWIRE) -- Hi-Crush Partners LP (NYSE:HCLP), or "Hi-Crush" or the "Partnership", announced today that the Board of Directors of its general partner has declared a quarterly cash distribution of $0.225 per unit on all common units, or $0.90 on an annualized basis, for the first quarter of 2018.
Upvote Downvote

 
Top MLP Gainers in the Week Ending April 13

2018-04-17 marketrealist
Legacy Reserves (LGCY), an upstream MLP involved in crude oil, natural gas, and NGLs (natural gas liquids) production, was the top MLP gainer in the week ending April 13, 2018. Legacy Reserves rallied 17.4% last week. The rally was mainly due to strong gains in crude oil prices.
Upvote Downvote

 
Is Hi-Crush Partners a Great Stock for Value Investors?

2018-04-11 zacks
Value investing is easily one of the most popular ways to find great stocks in any market environment. After all, who wouldn’t want to find stocks that are either flying under the radar and are compelling buys, or offer up tantalizing discounts when compared to fair value?
Upvote Downvote

 
Hi-Crush: Short-Term Pains, Long-Term Gains

2018-04-06 seekingalpha
Incoming supply concerns might still not be enough to handle demand, which means continued further price increases in sand.
Upvote Downvote

 
MLPs That Fell the Most in the Week Ended March 30

2018-04-03 editors.aws.marketrealist
Navios Maritime Midstream Partners (NAP), the MLP involved in marine transportation of fuel, including crude oil, refined products, and NGLs (natural gas liquids), was the MLP that fell the most last week, which ended March 30. It fell a massive 54.2%, which could be attributed mainly to its recent rating downgrade by JPMorgan Chase. It lowered NAP to “underweight,” which is equivalent to a “sell,” from “neutral,” which is equivalent to a “hold.
Upvote Downvote

 
Hi-Crush Partners LP Appoints Scott J. Preston as Chief Operating Officer

2018-04-02 globenewswire
HOUSTON, April 02, 2018 (GLOBE NEWSWIRE) -- Hi-Crush Partners LP (NYSE:HCLP), or “Hi-Crush”, today announced that Scott J. Preston has joined as Chief Operating Officer. In this newly created role, Mr. Preston will be responsible for the daily operations of Hi-Crush as well as the development and implementation of Hi-Crush’s ongoing growth strategy.
Upvote Downvote

 
Just The Numbers... Plus: Frac Sand Companies

2018-03-29 seekingalpha
Frac sand entities take several forms: as divisions of large oilfield service companies, as part of public industrial sand companies or limited partnerships, and as private companies.
Upvote Downvote

 
What Does The Abundance Of Recent Bearish News Mean For Sand Fracking Companies?

2018-03-27 seekingalpha
Unexpected FERC bear news took the MLP sector for a loop, but doesn't apply to sand fracking companies.
Upvote Downvote

 
Hi-Crush Partners LP Announces Timing of First Quarter 2018 Financial Results and Conference Call

2018-03-27 globenewswire
HOUSTON, March 27, 2018 (GLOBE NEWSWIRE) -- Hi-Crush Partners LP (NYSE:HCLP), or “Hi-Crush”, today announced that it will release its first quarter 2018 results after market close on Tuesday, May 1, 2018. This release will be followed by a conference call for investors at 7:30 a.m. Central Time (8:30 a.m. Eastern) on Wednesday, May 2, 2018. Hosting the call will be Robert E. Rasmus, Chief Executive Officer and Laura C.
Upvote Downvote

2
50 Top Basic Materials Dividend Yields For March

2018-03-27 seekingalpha
Coal, wood, glass, & chemicals topped March's basic materials sector for gains, calculated by broker 1-year targets on 3/23/18.
Upvote Downvote

 
Are MLPs Going Away?

2018-03-26 seekingalpha
MLP investors have certainly seen their conviction tested of late. Poor stock performance was recently compounded by the Federal Energy Regulatory Commission’s (FERC) ruling on cost of service contracts earlier this month. Although MLPs don’t pay tax, interstate natural gas pipeline tariffs based on cost-of-service have historically included an allowance for taxes paid by their investors. Following a court challenge by United Airlines, FERC has now disallowed this practice.
Upvote Downvote

 
A Look at MLP Subgroups in 2018 So Far

2018-03-23 editors.aws.marketrealist
In this article, we’ll analyze MLPs’ performance by subgroups. Upstream MLPs comprise the top-performing MLP subgroup in 2018 to date. This is mainly driven by strong performance from Legacy Reserves (LGCY), which has gained more than 140.0% since the start of this year.
Upvote Downvote

Related Articles

GNCA: Genocea Biosciences Analysis and Research Report

11h - Asif

Overview Genocea Biosciences is a biopharmaceutical company that discovers and develops novel cancer vaccines. The company use its proprietary discovery platform, ATLAS, to recall a patient’s pre-existing CD4+ and CD8+ T cell immune responses to their tumor to identify antigens for inclusion in vaccines that are designed to act through T cell (or cellular) immune responses. The company believe that using ATLAS to identify antigens for inclusion in cancer vaccines could lead to more immunogenic and efficacious cancer vaccines. In September 2017, the company announced a strategic shift to immuno-oncology and a focus on the development of neoantigen cancer vaccines. Currently, all of its research programs and product candidates in active development are at the preclinical stage. The company's most advanced program is its preclinical immuno-oncology program, GEN-009, a neoantigen cancer vaccine. The GEN-009 program uses ATLAS to identify patient neoantigens, or newly formed anti...

AMZN: Amazon.com, Inc Analysis and Research Report

11h - Asif

Overview Amazon.com opened its virtual doors on the World Wide Web in July 1995. The company seek to be Earth’s most customer-centric company. Amazon is guided by four principles: customer obsession rather than competitor focus, passion for invention, commitment to operational excellence, and long-term thinking. In each of its segments, the company serve its primary customer sets, consisting of consumers, sellers, developers, enterprises, and content creators. In addition, the company provide services, such as advertising services and co-branded credit card agreements. Amazon has organized its operations into three segments: North America, International, and Amazon Web Services (“AWS”). These segments reflect the way the Company evaluates its business performance and manages its operations. Additional information on its operating segments and its net sales is contained in Item 8 of Part II, “Financial Statements and Supplementary Data—Note 11—Segment Information.” The compan...

LPCN: Lipocine Inc Analysis and Research Report

2018-04-23 - Asif

Overview Lipocine is a specialty pharmaceutical company focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. The company's proprietary delivery technologies are designed to improve patient compliance and safety through orally available treatment options. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Lipocine has a portfolio of proprietary product candidates designed to produce favorable pharmacokinetic (“PK”) characteristics and facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. The company's lead product candidate, TLANDO™, is an oral testosterone replacement therapy (“TRT”) and is currently under review by the United States Food and Drug Administration (“FDA”) with a Prescription Drug User Fee Act (“...

CUSIP: 428337109